Drugs / FTL001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06410092 | Jun 2023 → Jan 2026 overdue | neoplasm | Sound Biopharmaceuticals Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FTL001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06410092 ↗ |
| Route | Intravenous | “IV infusion every 2 weeks” NCT06410092 ↗ |